Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfadiazine is a sulfonamide antibiotic used to treat or prevent infections caused by certain bacteria and parasites. It is commonly indicated for urinary tract infections, ear infections, meningitis, malaria, toxoplasmosis (especially in combination with pyrimethamine), trachoma, chancroid, inclusion conjunctivitis, nocardiosis, and as prophylaxis for rheumatic fever and meningitis[1][3][4][5]. Sulfadiazine acts as a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase (also known as dihydropteroate synthase), which is essential for folic acid synthesis in bacteria. By inhibiting this enzyme and interfering with the processing of para-aminobenzoic acid (PABA), sulfadiazine disrupts bacterial growth and replication[4][5]. It does not have activity against viral infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sulfadiazine.